Federal contract award
75N93023C00003
TO DEVELOP AN ORALLY AVAILABLE SMALL MOLECULE ANTIVIRAL DRUG, WITH TREATMENT OF YELLOW FEVER VIRUS INFECTION AS THE PRIMARY INDICATION.
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | NATIONAL INSTITUTES OF HEALTH NIAID |
| NAICS | 541715 — Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
| PSC | AN12 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | COST PLUS FIXED FEE |
| Obligations | $16.2M |
| Current contract value | $16.2M |
| Potential contract value / ceiling | $32.3M |
| Start date | Nov 15, 2022 |
| Current end date | Nov 30, 2027 |
| Potential end date | Nov 30, 2027 |
| Latest award activity | Jul 24, 2026 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 12 of 12 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Jul 24, 2026 | P00011 | $0 | TO DEVELOP AN ORALLY AVAILABLE SMALL MOLECULE ANTIVIRAL DRUG, WITH TREATMENT OF YELLOW FEVER VIRUS INFECTION AS THE PRIMARY INDICATION. |
| May 14, 2026 | P00010 | $3.8M | TO DEVELOP AN ORALLY AVAILABLE SMALL MOLECULE ANTIVIRAL DRUG, WITH TREATMENT OF YELLOW FEVER VIRUS INFECTION AS THE PRIMARY INDICATION. |
| Jan 28, 2026 | P00009 | $0 | TO DEVELOP AN ORALLY AVAILABLE SMALL MOLECULE ANTIVIRAL DRUG, WITH TREATMENT OF YELLOW FEVER VIRUS INFECTION AS THE PRIMARY INDICATION. |
| Aug 12, 2025 | P00008 | $0 | TO DEVELOP AN ORALLY AVAILABLE SMALL MOLECULE ANTIVIRAL DRUG, WITH TREATMENT OF YELLOW FEVER VIRUS INFECTION AS THE PRIMARY INDICATION. |
| Mar 13, 2025 | P00007 | $0 | TO DEVELOP AN ORALLY AVAILABLE SMALL MOLECULE ANTIVIRAL DRUG, WITH TREATMENT OF YELLOW FEVER VIRUS INFECTION AS THE PRIMARY INDICATION. |
| Jan 14, 2025 | P00006 | $0 | TO DEVELOP AN ORALLY AVAILABLE SMALL MOLECULE ANTIVIRAL DRUG, WITH TREATMENT OF YELLOW FEVER VIRUS INFECTION AS THE PRIMARY INDICATION. |
| Sep 17, 2024 | P00005 | $5.0M | TO DEVELOP AN ORALLY AVAILABLE SMALL MOLECULE ANTIVIRAL DRUG, WITH TREATMENT OF YELLOW FEVER VIRUS INFECTION AS THE PRIMARY INDICATION. |
| Apr 18, 2024 | P00003 | $0 | TO DEVELOP AN ORALLY AVAILABLE SMALL MOLECULE ANTIVIRAL DRUG, WITH TREATMENT OF YELLOW FEVER VIRUS INFECTION AS THE PRIMARY INDICATION. |
| Apr 18, 2024 | P00004 | $2.0M | TO DEVELOP AN ORALLY AVAILABLE SMALL MOLECULE ANTIVIRAL DRUG, WITH TREATMENT OF YELLOW FEVER VIRUS INFECTION AS THE PRIMARY INDICATION. |
| Sep 27, 2023 | P00002 | $0 | TO DEVELOP AN ORALLY AVAILABLE SMALL MOLECULE ANTIVIRAL DRUG, WITH TREATMENT OF YELLOW FEVER VIRUS INFECTION AS THE PRIMARY INDICATION. |
| Mar 17, 2023 | P00001 | $0 | TO DEVELOP AN ORALLY AVAILABLE SMALL MOLECULE ANTIVIRAL DRUG, WITH TREATMENT OF YELLOW FEVER VIRUS INFECTION AS THE PRIMARY INDICATION. |
| Nov 15, 2022 | 0 | $5.5M | TO DEVELOP AN ORALLY AVAILABLE SMALL MOLECULE ANTIVIRAL DRUG, WITH TREATMENT OF YELLOW FEVER VIRUS INFECTION AS THE PRIMARY INDICATION. |
Estimated positioning window
Nov 30, 2026 – May 30, 2027
70/100
Why this recompete signal
Contract timing and recorded acquisition signals at the time of calculation.
Stored score: 70/100. Available recorded signals: 65 points.
- Contract end 2027-11-30 (401 days from calculation)
- +25 points
- 155 historical awards in this buyer and category group
- +15 points
- 12 recorded award transactions
- +10 points
- Latest award action: 2026-07-24
- +5 points
- Parent award identifier recorded
- +0 points
- Solicitation identifier recorded
- +10 points
- Linked official forecast
- +0 points
- Calculated on
- 2026-10-25 10:18:04.631876+00:00
The historical group combines buyer, NAICS, and PSC. Multiple awards in this group do not by themselves establish repeated competitions.
Rule-based research score; it does not measure your chance of winning.
This older calculation does not retain a complete reproducible breakdown. Missing or changed inputs are not assigned invented points: Original award-value bonus input.
Recompete score calculated Oct 25, 2026.
Research next steps
- Check the linked forecast or SAM for a confirmed solicitation and current timing.
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.